



Pressemitteilung

Eurocor GmbH launches international multi-center registry - Valentines Trial II

- **45 centers from 16 countries registered**
- **Study for treatment of de novo lesions with DIOR™ DEB**

Bonn (Germany), February 14th, 2011 – Eurocor GmbH today began the new global multi-center registry - Valentines Trial II. Patients will be recruited from 45 centers around the globe; for a period starting today and ending on the occasion of CRT 2011 conference March, 1, 2011 or upon recruitment of 100 patients, whatever comes first.

The objective is to evaluate the efficacy of treatment with a Dior™ drug-eluting balloon. The success of Valentines Trial I demonstrated Eurocor's inventiveness in engaging a global clinical population through a very unique trial. "The primary objective of this multi-center, international registry is to assess clinical success and efficacy of the paclitaxel eluting balloon treatment for de novo lesions at 6-9 months follow up", says Dr. Rembert Pogge von Strandmann, Director – Clinical Department, Eurocor GmbH.

Additionally, many patients enrolled in the trial are slated to undergo an angiographic follow-up to evaluate angiographic late lumen loss and binary restenosis rate after treatment with a paclitaxel-eluting balloon.



The DIOR™ balloon demonstrated efficacy in preclinical trials and effectiveness for the de novo lesions in small vessel and bifurcation as well as in-stent restenosis application in several clinical trials. The purpose of the present study is to determine the safety and efficacy of the DIOR™ Balloon in comparison to POBA for non-stented de novo coronary artery lesions.

All data for analysis will be collected via an electronic data capture system and analyzed at the Cardiovascular Research Institute Data Coordinating Center of the Washington Hospital Center. Dr. Ron Waksman will be supported by three Principle investigators for the Study: Dr. Alfredo Rodriguez (Argentina), Dr. Antonio Serra (Spain) and Dr. Fazila Malik (Bangladesh).

The final Data of the Valentines Trial I will be announced Tuesday, March 1, 2011 at the CRT 2011 congress at 1:10 pm by Sigmund Silber, MD, Professor of Medicine.

The Company:

Eurocor GmbH is a rapidly growing European Life Sciences Technology Corporation specialising in the research, development and manufacture of cardiovascular and endovascular products. Eurocor is providing interventional cardiologists with innovative, coronary stent technologies and special cardiovascular and endovascular devices. The products manufactured by the company in Bonn are used in minimally invasive cardiovascular and peripheral surgery and comply with biological and biomechanical principles to offer highly flexible, adaptable solutions. Strong research and development, close collaboration with clinicians, outstanding quality standard philosophy and global scientific alliances lead to optimisation of clinically effective technologies. Eurocor has designed an innovative method for the delivery of drugs via a balloon catheter that is particularly compatible to the patient. For more information, please visit www.eurocor.de.

Follow us at http://twitter.com/Eurocor_Germany

Pressekontakt:

Blattwerk – Kommunikation für Unternehmen
Mittelweg 177
20149 Hamburg
Telefon: 040-41537634
E-Mail: eurocor@blattwerk-kommunikation.de